Paediatric Infectious Diseases Unit, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.
Ayder Comprehensive Specialised Hospital, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.
BMC Infect Dis. 2023 Feb 3;23(1):67. doi: 10.1186/s12879-023-08027-z.
Candida bloodstream infection (BSI) causes appreciable mortality in neonates and children. There are few studies describing the epidemiology of Candida BSI in children living in sub-Saharan Africa.
A retrospective descriptive study was conducted at three public sector hospitals in Cape Town, South Africa. Demographic and clinical details, antifungal management and patient outcome data were obtained by medical record review. Candida species distribution and antifungal susceptibility testing results were obtained from the National Health Laboratory Service database.
Of the 97 Candida BSI episodes identified during a five-year period, 48/97 (49%) were Candida albicans (C. albicans), and 49/97 (51%) were non-C. albicans species. The overall incidence risk was 0.8 Candida BSI episodes per 1000 admissions at Red Cross War Memorial Children's Hospital. Of the 77/97 (79%) Candida BSI episodes with available clinical information, the median age (interquartile range) at the time of BSI was 7 (1-25) months, 36/77 (47%) were associated with moderate or severe underweight-for-age and vasopressor therapy was administered to 22/77 (29%) study participants. Most of the Candida BSI episodes were healthcare-associated infections, 63/77 (82%). Fluconazole resistance was documented among 17%, 0% and 0% of C. parapsilosis, C. tropicalis and C. albicans isolates, respectively. All Candida isolates tested were susceptible to amphotericin B and the echinocandins. The mortality rate within 30 days of Candida BSI diagnosis was 13/75 (17%). On multivariable analysis, factors associated with mortality within 30 days of Candida BSI diagnosis included vasopressor therapy requirement during Candida BSI, adjusted Odds ratio (aOR) 53 (95% confidence interval 2-1029); hepatic dysfunction, aOR 13 (95% CI 1-146); and concomitant bacterial BSI, aOR 10 (95% CI 2-60).
The study adds to the limited number of studies describing paediatric Candida BSI in sub-Saharan Africa. Non-C. Albicans BSI episodes occurred more frequently than C. albicans episodes, and vasopressor therapy requirement, hepatic dysfunction and concomitant bacterial BSI were associated with an increase in 30-day mortality.
念珠菌血流感染(BSI)可导致新生儿和儿童死亡率显著升高。关于撒哈拉以南非洲地区儿童念珠菌 BSI 的流行病学研究较少。
本研究在南非开普敦的三家公立医院进行了一项回顾性描述性研究。通过病历回顾获取人口统计学和临床特征、抗真菌治疗管理和患者结局数据。从国家卫生实验室服务数据库获取念珠菌种分布和抗真菌药敏检测结果。
在五年期间,共确定了 97 例念珠菌 BSI 发作,其中 48/97(49%)为白色念珠菌(C. albicans),49/97(51%)为非白色念珠菌种。红十字会战争纪念儿童医院的念珠菌 BSI 发生率为每 1000 例入院 0.8 例。在有临床信息的 77/97(79%)例念珠菌 BSI 发作中,BSI 时的中位年龄(四分位距)为 7(1-25)个月,36/77(47%)与中度或重度体重不足有关,22/77(29%)研究参与者接受了血管加压素治疗。大多数念珠菌 BSI 发作是医源性感染,63/77(82%)。C. parapsilosis、C. tropicalis 和 C. albicans 分离株的氟康唑耐药率分别为 17%、0%和 0%。所有念珠菌分离株均对两性霉素 B 和棘白菌素类药物敏感。念珠菌 BSI 诊断后 30 天内的死亡率为 13/75(17%)。多变量分析显示,念珠菌 BSI 诊断后 30 天内死亡的相关因素包括念珠菌 BSI 期间需要血管加压素治疗,调整后优势比(aOR)53(95%置信区间 2-1029);肝功能障碍,aOR 13(95%CI 1-146);和合并细菌性 BSI,aOR 10(95%CI 2-60)。
该研究补充了描述撒哈拉以南非洲地区儿科念珠菌 BSI 的为数不多的研究。非白色念珠菌 BSI 发作比白色念珠菌 BSI 更常见,血管加压素治疗需求、肝功能障碍和合并细菌性 BSI 与 30 天死亡率增加相关。